Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you want to share the tickers?
You want to share those?
Good post by Nick Dean. GreenSpace Brands CEO Matthew von Teichman spoke with @BNNBloomberg’s @CatherineBizTV about Greenspace’s strategic partnership with @Emblem_Corp/@emblemcannabis to launch a #CBD-infused health and beauty line. $EMC.V $EMMBF
https://www.bnnbloomberg.ca/video/greenspace-brands-planning-brand-in-both-cannabis-and-pharmacy-channels-in-canada~1452777
Quarter earning
Does any one know when q2 earning are due?
I agree with you.
This stock will be just fine.
Nice
Can you be more specific on recognizing? Thanks
Or was it 80mm?
It was close to 180mm prior. If I’m not mistaking
Does anyone knows what’s happening with this stock? Why is dropping so much.
Thanks
These things happen with every CEO’s or former ones. Had nothing to do with this stock.
C-45 for Canada
When are the votes dO?
Nxttf I believe that’s what he means
Are you referring to another company or?
I also believe that it’s because MJ market has been fluctuating until Canada has more news on June 6 or 7
Hope not but feel around .80
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- ?Emblem Corp. (EMC.V) (EMC-WT.V) (“Emblem” or the “Company”), has announced today that Lorne Gertner has resigned as a director of the Company’s board of directors in order to focus his efforts on Hiku Brands. The Company thanks Mr. Gertner for his service as a director and wishes him all the best in his future endeavors. The Company has initiated a search for a new director to replace Mr. Gertner.
About Emblem
Emblem Corp., through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.
Does anyone know when they are up listing to Canadian exchange. Thx
Do you know what this projected price for this one after Canada legalizes.
???? Where
Good luck!
Thx.
Base on the name and their branding I was expecting $5-7 / share for this puppy. What are your thoughts
Thanks wolf. Do you know when the quarter earnings are coming up?
So what do you think about this stocks potential? Worth holding?
Good news coming possibly
It will but just hang on. This industry will have bigger share than NFL does
Ehave Solutions Gain Traction in Cannabis Industry -- CFN Mediahttps://finance.yahoo.com/news/ehave-solutions-gain-traction-cannabis-140000409.html
Gosh, feels like you are bi-polar bro, lol. Don’t mean in the bad way, just wait and be patient.
Anyone heard about Q4 earnings for 2017? When is it coming?
Everyone. This is a legit stock. Entire MJ market had little correction in the last few weeks. Hang on. This company will bring good harvest. Have patients and things will come
Did it really reached $0.50?
But this is a legit company. Compare to other pot stocks it’s in top 20’s I’d say for Canadian companies.
It’s a good company, just not sure why this is happening? Anyone knows any additional info?
TORONTO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (EMC.V) (EMC.WT) ("Emblem" or the "Corporation") announces that Mr. Gordon Fox, a director and founder of the Corporation, has tendered his resignation from the board of directors of the Corporation for personal reasons.
In light of Mr. Fox’s resignation, the board of directors has appointed Nick Dean, President and Chief Executive Officer of the Corporation, to replace Mr. Fox on Emblem’s board of directors. Mr. Dean’s appointment remains subject to the approval of the TSX Venture Exchange.
The Corporation thanks Mr. Fox for his significant contributions to the Corporation both as a director and previously as an executive officer of the Corporation. Mr. Fox has offered his services and help in the future as may be required on an advisory basis.
About Emblem
Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol “EMC” on the TSX Venture Exchange.
Forward-looking statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the use of proceeds from the Offering and the future results of operations, performance and achievements of the Corporation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Except as required by law, the Corporation disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Corporation from third parties and believes such information to be accurate but has not independently verified such information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information contact:
Ali Mahdavi
Emblem Corp.
(416) 962-3300
alimahdavi@emblemcorp.com
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
TORONTO, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (EMC.V) (EMC.WT) ("Emblem" or the "Company") is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the Underwriters’ (as defined below) over-allotment option (the "Offering"). In connection with the Offering, the Company issued 14,024,391 units of the Company (the "Units") and 25,000 8.0% convertible unsecured debentures of the Company due in 2021 (the "Convertible Debentures"). The Units were sold at a price per Unit of $2.05 for gross proceeds of $28,750,001.55 and the Convertible Debentures were sold at a price per Convertible Debenture of $1,000 for gross proceeds of $25,000,000, for total aggregate gross proceeds of $53,750,001.55. The Offering was underwritten by a syndicate of underwriters led by Eight Capital and included Canaccord Genuity Corp., Echelon Wealth Partners Inc. and GMP Securities L.P. (collectively, the "Underwriters").
Each Unit consists of one common share in the capital of the Company (each, a “Common Share”) and one common share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to acquire, subject to adjustment in certain circumstances, one additional Common Share at an exercise price of $2.70 per Common Share until February 2, 2020.
The Convertible Debentures will bear interest at an annual rate of 8.00% payable in arrears in equal installments semi-annually. The maturity date of the Convertible Debentures will be February 2, 2021 (the "Maturity Date"). Each Convertible Debenture will be convertible at the holder's option into Common Shares (the "Conversion Shares") at any time prior to the close of business on the business day immediately preceding the Maturity Date at a conversion price (the "Conversion Price") of $2.30 per Conversion Share, subject to adjustment in certain events as described in a debenture indenture dated as of February 2, 2018 entered into between the Company and Computershare Trust Company of Canada (the "Indenture"). Pursuant to the terms of the Indenture, the Company may require the conversion of all of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on not less than thirty days’ notice should the daily volume weighted average trading price of the outstanding Common Shares on the TSX Venture Exchange be greater than $3.45 for any ten consecutive trading days.
The net proceeds of the Offering will be partially used to fund the currently unfunded portion of the planning, design, development, construction and implementation (including the purchase of certain designated capital equipment) of the Company's new facility which is expected to be comprised of up to approximately 135,000 square feet of greenhouse space and 35,000 square feet of infrastructure space. The remaining net proceeds of the Offering will be used to fund pharmaceutical formulation development, including research and trials, and for general working capital purposes, which may include establishing new international distribution channels in jurisdictions where there is a federal legal framework for medical cannabis and the associated costs of compliance with applicable regulatory requirements. For additional details regarding the use of proceeds of the Offering, please see the Company's short form prospectus dated January 29, 2018 which is available under the Company's profile at SEDAR at www.sedar.com.
The Company also announces that holders of $15,000,000 of the Company’s previously issued convertible debentures due November 16, 2020 converted their debentures into Common Shares at the stated conversion price of $1.95 per Common Share. In connection with the conversion, Emblem issued 7,692,307 Common shares to the debenture holders.
Upon completion of the Offering the Company will have a cash and cash equivalents balance of approximately $87,000,000.
The securities offered in the Offering have not been, and will not be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor will there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Emblem
Emblem is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol “EMC” on TSX Venture Exchange.
Forward-looking statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the use of proceeds from the Offering and the future results of operations, performance and achievements of the Company. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information contact:
Ali Mahdavi
Emblem Corp.
(416) 962-3300
alimahdavi@emblemcorp.com